Terfenadine

Terfenadine
Clinical data
Trade names	Seldane, Triludan, Teldane
AHFS/Drugs.com	Multum Consumer Information
MedlinePlus	a600034
Routes of; administration	By mouth
ATC code	R06AX12 (WHO) ;
Legal status
Legal status	Withdrawn;
Pharmacokinetic data
Protein binding	70%
Metabolism	Hepatic (CYP3A4)
Metabolites	Fexofenadine
Elimination half-life	3.5 hours
Identifiers
	IUPAC name (RS)-1-(4-tert-butylphenyl)-4-{4-[hydroxy(diphenyl)methyl]piperidin-1-yl}-butan-1-ol;
CAS Number	50679-08-8 ;
PubChem CID	5405;
IUPHAR/BPS	2608;
DrugBank	DB00342 ;
ChemSpider	5212 ;
UNII	7BA5G9Y06Q;
KEGG	D00521 ;
ChEMBL	ChEMBL17157 ;
CompTox Dashboard (EPA)	DTXSID2023642 ;
ECHA InfoCard	100.051.537
Chemical and physical data
Formula	C32H41NO2
Molar mass	471.685 g·mol−1
3D model (JSmol)	Interactive image;
Chirality	Racemic mixture
	SMILES OC(c1ccccc1)(c2ccccc2)C4CCN(CCCC(O)c3ccc(cc3)C(C)(C)C)CC4;
	InChI InChI=1S/C32H41NO2/c1-31(2,3)26-18-16-25(17-19-26)30(34)15-10-22-33-23-20-29 (21-24-33)32(35,27-11-6-4-7-12-27)28-13-8-5-9-14-28/ h4-9,11-14,16-19,29-30,34-35H,10,15,20-24H2,1-3H3 ; Key:GUGOEEXESWIERI-UHFFFAOYSA-N ;
	(what is this?) (verify)

Terfenadine is an antihistamine formerly used for the treatment of allergic conditions. It was brought to market by Hoechst Marion Roussel (now Sanofi) and was marketed under various brand names, including Seldane in the United States, Triludan in the United Kingdom, and Teldane in Australia.^[1] It was superseded by fexofenadine in the 1990s due to the risk of a particular type of disruption of the electrical rhythms of the heart (specifically cardiac arrhythmia caused by QT interval prolongation) and has been withdrawn from markets worldwide.^[2]^: 53

^ Cite error: The named reference jama96 was invoked but never defined (see the help page).
^ Horak F (2010). "Antialergic and Vasoactive Drugs for Allergic Rhinitis Chapter 4". In Pawankar R, Holgate ST, Rosenwasser LJ (eds.). Allergy Frontiers:Therapy and Prevention. Vol. 5. Springer Science & Business Media. ISBN 978-4-431-99362-9.

[jama96-1] Cite error: The named reference jama96 was invoked but never defined (see the help page).

[2] Horak F (2010). "Antialergic and Vasoactive Drugs for Allergic Rhinitis Chapter 4". In Pawankar R, Holgate ST, Rosenwasser LJ (eds.). Allergy Frontiers:Therapy and Prevention. Vol. 5. Springer Science & Business Media. ISBN 978-4-431-99362-9.

[1]

[2]